Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. is a biopharmaceutical company focusing on discovering, developing, and commercializing innovative medicines. It is headquartered in Foster City, California, and operates in more than 35 countries worldwide. Gilead Sciences, Inc. is developing treatments for HIV/AIDS, liver diseases, cancer, and other life-threatening illnesses.
Company Info
US3755581036
375558103
Jan 22, 1992
Highlights
$127.61B
$4.86
21.09
0.21
$28.73B
$23.07B
$9.89B
$59.82 - $119.12
$115.04
1.89%
2.40
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Gilead Sciences, Inc. (GILD) returned 11.75% year-to-date (YTD) and 57.04% over the past 12 months. Over the past 10 years, GILD returned 2.76% annually, underperforming the S&P 500 benchmark at 10.89%.
GILD
11.75%
-1.95%
17.75%
57.04%
10.94%
2.76%
^GSPC (Benchmark)
1.30%
12.79%
1.49%
12.35%
15.12%
10.89%
Monthly Returns
The table below presents the monthly returns of GILD, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.23% | 17.60% | -1.29% | -4.92% | -3.79% | 11.75% | |||||||
| 2024 | -3.39% | -7.87% | 2.64% | -10.99% | -1.43% | 8.06% | 10.86% | 3.87% | 7.12% | 5.94% | 4.23% | 0.61% | 18.68% |
| 2023 | -2.22% | -4.06% | 4.01% | -0.92% | -6.41% | 1.14% | -1.21% | 0.45% | -1.05% | 4.80% | -2.47% | 6.72% | -1.99% |
| 2022 | -5.41% | -12.06% | -0.32% | -0.19% | 9.29% | -3.50% | -3.33% | 6.23% | -1.70% | 27.18% | 11.94% | -1.44% | 23.63% |
| 2021 | 12.60% | -6.40% | 6.46% | -1.79% | 4.16% | 5.25% | -0.83% | 6.57% | -3.06% | -7.12% | 6.24% | 6.41% | 29.95% |
| 2020 | -2.74% | 9.75% | 8.79% | 12.36% | -7.35% | -0.26% | -9.63% | -4.00% | -4.34% | -7.98% | 4.33% | -2.89% | -6.70% |
| 2019 | 11.93% | -7.13% | 0.95% | 0.05% | -4.29% | 9.56% | -3.02% | -3.02% | 0.68% | 0.52% | 5.54% | -2.45% | 7.88% |
| 2018 | 16.97% | -6.05% | -3.56% | -4.19% | -6.69% | 5.95% | 9.87% | -2.70% | 2.75% | -11.70% | 5.51% | -12.32% | -9.92% |
| 2017 | 1.17% | -2.72% | -2.89% | 0.93% | -5.34% | 9.95% | 7.50% | 10.01% | -2.61% | -7.48% | -0.24% | -3.54% | 2.96% |
| 2016 | -17.98% | 5.12% | 5.79% | -3.97% | -1.30% | -3.64% | -4.74% | -1.37% | 1.56% | -6.94% | 0.09% | -2.21% | -27.59% |
| 2015 | 11.21% | -1.24% | -5.22% | 2.43% | 11.70% | 4.66% | 0.67% | -10.85% | -6.18% | 10.12% | -2.01% | -4.09% | 8.63% |
| 2014 | 7.39% | 2.65% | -14.41% | 10.77% | 3.47% | 2.09% | 10.42% | 17.49% | -1.03% | 5.21% | -10.43% | -6.04% | 25.51% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 94, GILD is among the top 6% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Gilead Sciences, Inc. provided a 3.02% dividend yield over the last twelve months, with an annual payout of $3.10 per share. The company has been increasing its dividends for 9 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $3.10 | $3.08 | $3.00 | $2.92 | $2.84 | $2.72 | $2.52 | $2.28 | $2.08 | $1.84 | $1.29 |
Dividend yield | 3.02% | 3.33% | 3.70% | 3.40% | 3.91% | 4.67% | 3.88% | 3.65% | 2.90% | 2.57% | 1.27% |
Monthly Dividends
The table displays the monthly dividend distributions for Gilead Sciences, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.79 | $0.00 | $0.00 | $0.79 | |||||||
| 2024 | $0.00 | $0.00 | $0.77 | $0.00 | $0.00 | $0.77 | $0.00 | $0.00 | $0.77 | $0.00 | $0.00 | $0.77 | $3.08 |
| 2023 | $0.00 | $0.00 | $0.75 | $0.00 | $0.00 | $0.75 | $0.00 | $0.00 | $0.75 | $0.00 | $0.00 | $0.75 | $3.00 |
| 2022 | $0.00 | $0.00 | $0.73 | $0.00 | $0.00 | $0.73 | $0.00 | $0.00 | $0.73 | $0.00 | $0.00 | $0.73 | $2.92 |
| 2021 | $0.00 | $0.00 | $0.71 | $0.00 | $0.00 | $0.71 | $0.00 | $0.00 | $0.71 | $0.00 | $0.00 | $0.71 | $2.84 |
| 2020 | $0.00 | $0.00 | $0.68 | $0.00 | $0.00 | $0.68 | $0.00 | $0.00 | $0.68 | $0.00 | $0.00 | $0.68 | $2.72 |
| 2019 | $0.00 | $0.00 | $0.63 | $0.00 | $0.00 | $0.63 | $0.00 | $0.00 | $0.63 | $0.00 | $0.00 | $0.63 | $2.52 |
| 2018 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $2.28 |
| 2017 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $2.08 |
| 2016 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.47 | $0.00 | $0.00 | $0.47 | $0.00 | $0.00 | $0.47 | $1.84 |
| 2015 | $0.43 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.43 | $1.29 |
Dividend Yield & Payout
Dividend Yield
Gilead Sciences, Inc. has a dividend yield of 3.02%, which is quite average when compared to the overall market.
Payout Ratio
Gilead Sciences, Inc. has a payout ratio of 40.31%, which is quite average when compared to the overall market. This suggests that Gilead Sciences, Inc. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Gilead Sciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Gilead Sciences, Inc. was 70.82%, occurring on Jun 6, 1994. Recovery took 300 trading sessions.
The current Gilead Sciences, Inc. drawdown is 12.09%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -70.82% | Jan 28, 1992 | 596 | Jun 6, 1994 | 300 | Aug 11, 1995 | 896 |
| -60.43% | Sep 26, 1997 | 234 | Aug 31, 1998 | 127 | Mar 4, 1999 | 361 |
| -59.67% | Sep 8, 1999 | 73 | Dec 20, 1999 | 169 | Aug 21, 2000 | 242 |
| -58.81% | Jan 29, 1996 | 117 | Jul 15, 1996 | 298 | Sep 17, 1997 | 415 |
| -53.46% | Sep 26, 2000 | 73 | Jan 9, 2001 | 91 | May 21, 2001 | 164 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Gilead Sciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Gilead Sciences, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 2.1% positive surprise.
Valuation
The Valuation section provides an overview of how Gilead Sciences, Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for GILD, comparing it with other companies in the Drug Manufacturers - General industry. Currently, GILD has a P/E ratio of 21.1. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for GILD compared to other companies in the Drug Manufacturers - General industry. GILD currently has a PEG ratio of 0.2. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GILD relative to other companies in the Drug Manufacturers - General industry. Currently, GILD has a P/S ratio of 4.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GILD in comparison with other companies in the Drug Manufacturers - General industry. Currently, GILD has a P/B value of 6.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |